Belgium's Ablynx in Merck cancer research tie-up: firm

Belgian biotechnology company Ablynx said on Monday it has signed a cancer research cooperation accord with US pharmaceuticals giant Merck & Co. which could be worth up to 1.7 billion euros ($2.3 billion).

The contract, to identify proteins which may lead to cancer immunotherapy treatments, involves an initial payment of 20 million euros plus 10.7 million euros for the three-year research programme.

Subsequent royalties on sales could lead to payment of 1.7 billion euros, Ablynx said in a statement.

Merck will be responsible for development, manufacture and say of any treatments generated by the research.

Immunotherapy treatments aim to boost the body's own immune response so as to fight .

Related Stories

German drug maker Merck ups forecast for 2013

date Nov 14, 2013

German chemicals and pharmaceuticals giant Merck KGaA said Thursday it is raising its full-year operating profit forecast thanks to improving sales and positive cost-cutting effects.

Higher prices for MS drug help drug firm Merck

date May 14, 2013

(AP)—Higher prices for its multiple sclerosis drug Rebif helped German pharmaceutical and high-tech materials company Merck KGaA post a 54 percent rise in first-quarter profit.

Recommended for you

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.